Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
It is increasingly looking like artificial intelligence (AI) isn't just a fad. It is a transformative technology that could introduce paradigm shifts across many sectors and industries. Although some ...
Alphabet is already a leader in AI and boasts attractive growth avenues beyond this industry. Recursion Pharmaceuticals has a long way to go before demonstrating that its approach works. It is ...
Hosted on MSN
1 beaten-down AI stock to buy and 1 to avoid
Alphabet is already a leader in AI and boasts attractive growth avenues beyond this industry. Recursion Pharmaceuticals has a long way to go before demonstrating that its approach works. 10 stocks we ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results